Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients

Cancer Letters

Volumn 251, Issue 2, 2007, Pages 296-301

  Caine, Graham J ^a   Ryan, Peter ^b   Lip, Gregory Y H ^a   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Angiopoietin soluble P selectin; Prostate cancer; Radical prostatectomy; VEGF; von Willebrand factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; D DIMER; FIBRINOGEN; HORMONE; PADGEM PROTEIN; TUMOR MARKER; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MALE; NEPHELOMETRY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; THROMBOCYTE;

AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; BLOOD COAGULATION; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; P-SELECTIN; PLATELET ACTIVATION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 34247578031     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.11.026     Document Type: Article

References (30)

1. Lip G.Y.H., Chin B.S.P., and Blann A.D. Cancer and the prothrombotic state. Lancet Oncol. 3 (2002) 27-34
2. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990) 4-6
3. Linenberger M.L., and Wittkowsky A.K. Thromboembolic complications of malignancy. Oncology 19 (2005) 853-861
4. Donati M.B., and Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol. 106 (2001) 18-24
5. Johnson M.J., Sproule M.W., and Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin. Oncol. 11 (1999) 105-110
6. Rickles F.R., Levine M., and Edwards R.L. Hemostatic alterations in cancer patients. Cancer Metastasis Rev. 11 (1992) 237-248
7. Falanga A., and Rickles F.R. Pathophysiology of the thrombophilic state in the cancer patient. Semin. Thromb. Hemost. 25 (1999) 173-182
8. Blann A.D., Gurney D., Wadley M., Bareford D., Stonelake P., and Lip G.Y. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul. Fibrinol. 12 (2001) 43-50
9. Haznedaroglu I.C., Benekli M., Ozcebe O., Savas M.C., Gullu I.H., Dundar S.V., and Kirazli S. Serum L-selectin and P-selectin levels in lymphomas. Haematologia 30 (2000) 27-30
10. Yasasever V., Tas F., Duranyildiz D., Camlica H., Kurul S., and Dalay N. Serum levels of the soluble adhesion molecules in patients with malignant melanoma. Pathol. Oncol. Res. 6 (2000) 42-45
11. Levine M.N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb. Haemost. 78 (1997) 133-136
12. Pritchard K.I., Paterson A.H., Paul N.A., Zee B., Fine S., and Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J. Clin. Oncol. 14 (1996) 2731-2737
13. Falanga A., Ofosu F.A., Cortelazzo S., Delaini F., Consonni R., Caccia R., Longatti S., Maran D., Rodeghiero F., and Pogliani E. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br. J. Haematol. 85 (1993) 745-750
14. Caine G.J., Blann A.D., Stonelake P.S., Ryan P., and Lip G.Y. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur. J. Clin. Invest. 33 (2003) 883-890
15. Kitagawa Y., Dai J., Zhang J., Keller J.M., Nor J., Yao Z., and Keller E.T. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res. 65 (2005) 10921-10929
16. Wurmbach J.H., Hammerer P., Sevinc S., Huland H., and Ergun S. The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res. 20 (2000) 5217-5220
17. George D.J., Regan M.M., Oh W.K., Tay M.H., Manola J., Decalo N., Duggan S., Dewolf W.C., Kantoff P.W., and Bubley G.J. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 63 (2004) 327-332
18. Stefanou D., Batistatou A., Kamina S., Arkoumani E., Papachristou D.J., and Agnantis N.J. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 18 (2004) 155-160
19. Gurney D., Poole C., Kehoe S., Lip G.Y., and Blann A.D. Soluble P-selectin is influenced by cancer chemotherapy. Platelets 12 (2001) 37-38
20. Ma L., Perini R., McKnight W., Dicay M., Klein A., Hollenberg M.D., and Wallace J.L. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc. Natl. Acad. Sci. USA 102 (2005) 216-220
21. McCabe N.P., Selman S.H., and Jankun J. Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase. Prostate 66 (2006) 779-787
22. Caine G.J., Lip G.Y., and Blann A.D. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann. Med. 36 (2004) 273-277
23. Caine G.J., Lip G.Y., Stonelake P.S., Ryan P., and Blann A.D. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb. Haemost. 92 (2004) 185-190
24. Kisucka J., Butterfield C.E., Duda D.G., Eichenberger S.C., Saffaripour S., Ware J., Ruggeri Z.M., Jain R.K., Folkman J., and Wagner D.D. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc. Natl. Acad. Sci. USA 103 (2006) 855-860
25. Banks R.E., Forbes M.A., Kinsey S.E., Stanley A., Ingham E., walters C., and Selby P.J. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer 77 (1998) 956-964
26. Brill A., Elinav H., and Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc. Res. 63 (2004) 226-235
27. Salgado R., Vermeulen P.B., Benoy I., Weytjens R., Huget P., Van Marck E., and Dirix L.Y. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br. J. Cancer 80 (1999) 892-897
28. Lind A.J., Wikstrom P., Granfors T., Egevad L., Stattin P., and Bergh A. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 62 (2005) 394-399
29. Shariat S.F., Anwuri V.A., Lamb D.J., Shah N.V., Wheeler T.M., and Slawin K.M. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J. Clin. Oncol. 22 (2004) 1655-1663
30. G.J. Caine, P.S. Stonelake, G.Y.H. Lip, A.D. Blann, Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer. Cancer Lett., in press, doi:10.1016/j.canlet.2006.06.011.